Welcome to BioSeeker Group!

Triple Analysis: Leukemia, Melanoma and Apoptosis

Additional Information

Published Date Jun 12, 2013
Special Offer

You can deduct the full value of this report within 30 days of purchase towards a Cancer Highlights subscription.
Read more about becoming a Cancer Highlights subscriber here.

Pages 3945
PDF Fact Sheet View Fact Sheet for the report Triple Analysis: Leukemia, Melanoma and Apoptosis in PDF
Format PDF
Publisher BioSeeker Group
Product Line

Find the Triple Analysis Report in oncology which best suits your needs by selecting any three (3) out of these 14 high impact Cancer Focus Areas.

Availability: In stock

$3,450.00

Quick Overview

This triple analysis focuses on cancer drug development strategies in both Leukemia and Melanoma and by the mechanism/target/effect of Apoptosis.

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Triple Analysis: Leukemia, Melanoma and Apoptosis.

    To find out more about Triple Analysis: Leukemia, Melanoma and Apoptosis, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Triple Analysis: Leukemia, Melanoma and Apoptosis is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

This triple analysis focuses on cancer drug development strategies in both Leukemia and Melanoma and by the mechanism/target/effect of Apoptosis. Each of these three individual parts is evaluated according to standardized criteria in a five pillar pipeline drug assessment methodology to compare drug development strategies in oncology. This makes it easy to find and compare analysis not only within one single cancer focus area but also between different areas.

Below is a short synopsis of each part included in this report:

Part I: Leukemia
The leukemia report part comprises defined and up to date development strategies for 313 leukemia drugs within the portfolio of 186 investigators, from Ceased to Marketed. This part extensively analyses their 204 identified drug targets, organized into 193 drug target strategies, and assesses them in eight different compound strategies and and eight subindications of leukemia.
This part is based on the following publication:
A Decision Support Tool for Optimizing The Leukemia Pipeline: From Research and Development to Market

Part II: Melanoma
The melanoma drug report part comprises defined and up to date development strategies for 282 drugs within the portfolio of 164 companies world-wide, from Ceased to Marketed. The report extensively analyses their 226 identified drug targets, organized into 187 drug target strategies, and assesses them in melanoma.
This part is based on the following publication:
Melanoma Drug Development Analysis: From First-in-Class to Best-in-Class?

Part III: Apoptosis
The apoptotic cancer drug report part comprises defined and up to date development strategies for 234 drugs in oncology within the portfolio of 158 companies world-wide, from Ceased to Marketed. The report extensively analyses their 181 identified drug targets, organized into 157 drug target strategies, and assesses them in 69 cancer indications.
This part is based on the following publication:
Commercializing Apoptotic Drugs in Cancer: The Faster Route to Consider Your Options and Position of Others

The report is written for you to understand and assess the impact of competitor entry and corresponding changes to development strategies for your own portfolio products. It helps teams to maximize molecule value by selecting optimal development plans and manage risk and uncertainty. The report serves as an external commercial advocate for pharmaceutical companies’ pipeline and portfolio planning (PPP) in cancer by:

* Providing you with competitive input to the R&D organization to guide development of early product ideas and ensure efforts are aligned with business objectives

* Assisting you to make informed decisions in selecting cancer indications that are known to be appropriate for your drug’s properties

* Analyzing, correlating and integrating valuable data sources in order to provide accurate data for valuation of pipeline, in-licensing and new business opportunities

* Providing you with commercial analytic support for due diligence on in-licensing and acquisition opportunities

* Supporting development of integrative molecule, pathway and disease area strategies

* Integrating knowledge for you to consider the therapeutic target for the highest therapeutic outcome and return on investment

This report provides systems, analytical and strategic support both internally to PPP and to stakeholders across your own organization. The report will also be an important part of creating and implementing a market development plan for cancer drugs to insure that the optimal market conditions exist by the time the products are commercialized.

Key Topics Covered:

Part I: Leukemia
5.1 The Scope of this Report 29
6 Consider the Therapeutic Target Among Leukemia Drugs for the Highest Therapeutic Outcome and Return on Investment (204 Drug Targets) 33-443
7 Emerging New Products to Established Ones: Drug Target Strategies of Leukemia Drugs by their Highest Stage of Development (193 Drug Target Strategies and 313 Leukemia Drugs) 444-727
8 Compound Strategies at Work: Competitive Benchmarking of Leukemia Drugs by Compound Strategy (8 Compound Strategies) 679-728
9 Selecting Subindication for Leukemia Drugs (8 Subindications of Leukemia) 729-762
10 Pipeline and Portfolio Planning: Competitive Benchmarking of the Leukemia Drug Pipeline by Investigator (186 Companies) 763-1,129
11 Disclaimer 1130
12 Drug Index 1131
13 Company Index 1140
Figures: Includes 6 Figures
Tables: Includes 253 Tables
Total Number of Pages: 1,147

Part II: Melanoma
5.1 The Scope of this Report 26
6 Consider the Therapeutic Target Among Melanoma Drugs for the Highest Therapeutic Outcome and Return on Investment (226 Drug Targets) 30-467
7 First-in-Class and Me-too Analysis of Melanoma Drugs (187 Drug Target Strategies and 282 Drugs) 468-677
8 Is First-in-Class the Best-in-Class? 488-678
9 Compound Strategies at Work: Competitive Benchmarking of Melanoma Drugs by Compound Strategy (7 Compound Strategies) 679-710
10 The Competition Through Close Mechanistic Approximation of Melanoma Drugs 711
11 Pipeline and Portfolio Planning: Competitive Benchmarking of the Melanoma Drug Pipeline by Company (164 Companies and 282 Drugs) 716-1165
12 Disclaimer 1166
Figures: Includes 5 Figures
Tables: Includes 222 Tables
Total Number of Pages: 1,181

Part III: Apoptosis
5.1 The Scope of this Report 33
6 Consider the Therapeutic Target Among Apoptotic Drugs in Oncology for the Highest Therapeutic Outcome and Return on Investment (181 Drug Targets) 37-416
7 Emerging New Products to Established Ones: Drug Target Strategies of Apoptotic Drugs in Oncology by their Highest Stage of Development (157 Drug Target Strategies and 234 Drugs) 417-622
8 Compound Strategies at Work: Competitive Benchmarking of Apoptotic Cancer Drugs by Compound Strategy(7 Compound Strategies) 623-660
9 Selecting Indication for Apoptotic Drugs in Oncology (69 Cancer Indications) 661-776
10 Pipeline and Portfolio Planning: Competitive Benchmarking of the Apoptotic Drug Pipeline in Oncology by Investigator (158 Investigators and 234 Drugs) 777-1601
Disclaimer 1602
11 Drug Index 1603
12 Company Index 1611
Figures: Includes 7 Figures
Tables: Includes 315 Tables
Total Number of Pages: 1,617

This Report Includes the Following Companies:
3M Pharmaceuticals
3SBio
4SC
AB Science
Abbott
AbbVie
Abiogen
Access
Actelion
Actinium Pharmaceuticals
Adherex
Advanced Life Sciences
Advaxis
AEgera
AEterna Zentaris
Agenus
Aida Pharmaceuticals
Aileron Therapeutics
Alexion
Alfa Wassermann
Alnylam
AlphaVax
Altor BioScience
Ambit Biosciences
Ambrilia Biopharma
Amgen
Anadys Pharmaceuticals
Anaphore
Anavex Life Sciences
AngioChem
Antisense Pharma
Antisoma
Aphios
Apogenix
ApopLogic Pharmaceuticals
Apotex
Arca biopharma
Ariad
Arno Therapeutics
ArQule
Array BioPharma
Asahi Kasei Pharma
Ascenta Therapeutics
Astellas
Astex Pharmaceuticals
Astex Therapeutics
AstraZeneca
Attenuon
Avila Therapeutics
Basilea Pharmaceutica
Bayer
Bio-Medisinsk Innovasjon
Bio-Path Holdings
BioAlliance Pharma
BioAxone
Biocad
BioCryst Pharmaceuticals
Bioenvision
Biogen Idec
BioInvent
Biokine Therapeutics
BioLineRx
Biomas
Bionovo
BioNTech
BioNumerik
BioSante
Biosceptre
Biotech Ltd
Biotecnol
Bioton
BioVex
Boehringer Ingelheim
Bristol-Myers Squibb
BTG
Callisto Pharmaceuticals
Cancer Research Technology
CDG Therapeutics
Celator Pharmaceuticals
Celera
Celgene
Cell Therapeutics
Celldex Therapeutics
Celtic Pharma
Cephalon
ChemoCentryx
Chlorogen
Choongwae
Chroma Therapeutics
CJ Corp
Clavis Pharma
Cleveland BioLabs
CombinatoRx
Cornerstone Pharmaceuticals
Coronado Biosciences
Cosmo Pharmaceuticals
Critical Outcome Technologies
CSL
Curacyte
CureTech
Curis
Cyclacel
Cylene Pharmaceuticals
Cynvec
CytImmune Sciences
Cytochroma
Cytokinetics
CytRx
Daewoong
Daiichi Sankyo
Dainippon Sumitomo Pharma
Dara Biosciences
Deciphera Pharmaceuticals
DeveloGen
DiaMedica
DNAVEC
Dong-A
Eisai
Eleos
Eli Lilly
Emergent BioSolutions
EntreMed
Enzon
EpiCept
Epizyme
Erimos
Esperance Pharmaceuticals
Exelixis
ExonHit Therapeutics
Flamel Technologies
Gemin X Biotechnologies
Genencor
Genentech
Genmab
Genta
GenVec
Genzyme
Gerolymatos
Geron
Gilead Sciences
GlaxoSmithKline
GlycoGenesys
GlycoMimetics
Glycotope
GPC Biotech
Gradalis
Green Cross
Hanmi
Harbor BioSciences
Hayashibara
Heber Biotec
Hemispherx Biopharma
Hoffmann-La Roche
Human Genome Sciences
Ichor Medical Systems
Idera Pharmaceuticals
IDM Pharma
IkerChem
ImClone Systems
Immune Pharmaceuticals
Immunocore
ImmunoGen
Immunomedics
Immunovaccine
ImmuPharma
Incyte Corporation
InDex Pharmaceuticals
Inex
Infinity Pharmaceuticals
Innate Pharma
InNexus Biotechnology
Innovive
Inotek
Inovio
Insmed
Insys Therapeutics
Intas Biopharmaceuticals
Intracel
Intradigm
Intrexon
Introgen Therapeutics
Ipsen
Isis Pharmaceuticals
ISU ABXIS
Italfarmaco
Jennerex Biotherapeutics
Johnson & Johnson
KAEL-GemVax
KaloBios
Kalypsys
Kanisa
Karyon-CTT
Keryx Biopharmaceuticals
Kiadis
Kinex
Kyowa Hakko Kirin
Leo
LFB Biotechnologies
LG Life Sciences
Ligand
Lipotek
Lorus Therapeutics
Mannkind
MAT Biopharma
MaxCyte
MaxoCore Pharmaceuticals
Meda
MediGene
Medisyn Technologies
Memgen
Merck & Co
Merck KGaA
MethylGene
Micromet
Mitsubishi Tanabe Pharma
Mochida
Mojave Therapeutics
MolMed
Mologen
Nereus Pharmaceuticals
Nerviano Medical Sciences
NIH
Nippon Shinyaku
Non-industrial source
Novacea
NovaLead
Novartis
Novelix
Novogen
Oasmia
Oncalis
Onconova
Oncothyreon
Oncovir
OSI Pharmaceuticals
Otsuka
Oxford BioMedica
OXiGENE
Pacific Biotech
PanaGin
Patrys
PBL Therapeutics
Pfizer
Pharmacyclics
PharmaMar
Pharminox
PhiloGene
PIERIS Proteolab
Pierre Fabre
Piramal
Portola Pharmaceuticals
Prochon Biotech
Progen
ProMetic Life Sciences
QLT
Reata Pharmaceuticals
Regulon
Reliance Life Sciences
Rexahn
Rigel
Rosetta Genomics
Sangamo BioSciences
Sanofi
Sanofi-Aventis
Santaris Pharma
Santhera Pharmaceuticals
Sareum
SBI Biotech
SBIO
Scancell
Seattle Genetics
Semafore Pharmaceuticals
Senesco Technologies
Sepal Pharma
Servier
Shenogen
Shire
Sidus
Sigma-Tau
Simcere Pharmaceuticals
Solbec Pharmaceuticals
Southern Research Institute
Spirogen
SRI International
Stemline Therapeutics
Sunesis
SuperGen
Swedish Orphan Biovitrum
Switch Pharma
SymBio Pharmaceuticals
Symbiotec
Synageva BioPharma
Synta Pharmaceuticals
Syntrix
Takeda
Talon Therapeutics
Tapestry Pharmaceuticals
Targa Therapeutics
TargeGen
Targepeutics
Tau Therapeutics
Taxolog
TeGenero
Telik
TetraLogic Pharmaceuticals
Teva
Thallion Pharmaceuticals
Therion Biologics
Tigris Pharmaceuticals
to-BBB
Tolerx
TopoTarget
Tracon Pharmaceuticals
Transgene
Trion Pharma
UMN Pharma
Valeant
ValiRx
VBL Therapeutics
Vectura
Velacor Therapeutics
Vertex Pharmaceuticals
Vical
Vion Pharmaceuticals
VioQuest
VioQuest Pharmaceuticals
Viragen
Viralytics
ViroTarg
VM Discovery
WntResearch
XBiotech
Xencor
Xerion
Yamasa Corporation
York Pharma
Zenyaku Kogyo
A Shortlist of Drugs Included are:
131I-tositumomab
AEB071
AEG-35156
agatolimod
aldesleukin
alemtuzumab
ALT-801
alvocidib
AME-133
amonafide malate
amsacrine
APG-101
APO-866
ARQ-197
ARRY-438162
AS-101
AS-1411
astuprotimut-r
Auto TAG vaccine
axitinib
barasertib
bardoxolone methyl
belinostat
bevacizumab
bisantrene
BMS-663513
BMS-936558
bortezomib
bosutinib
Buparlisib
BZL-101
Cabozantinib
canfosfamide hydrochloride
CB-10-01
cenersen
cilengitide
cintredekin besudotox
cladribine
clofarabine
conatumumab
cositecan
crolibulin
CSF-GM
CT-011
cytarabine ocfosfate
cytarabine, injectable
dasatinib
daunorubicin
decitabine
denenicokin
denileukin diftitox
dinaciclib
dovitinib lactate
dulanermin
E7449
elacytarabine
EMD-273063
endostatin
enocitabine
entinostat
enzastaurin hydrochloride
epirubicin
everolimus
Exherin
fosbretabulin tromethamine
fresolimumab
ganetespib
ganitumab
gataparsen
gefitinib
gemtuzumab ozogamicin
glembatumumab vedotin
golvatinib
GSK-1120212
GSK-2118436
GT-111
GV-1001
GVAX
HE-3235
Hi-8 MEL
histamine dihydrochloride
ibritumomab tiuxetan
idarubicin
idronoxil
imatinib mesilate
imetelstat
INCB-24360
interferon
interferon (alpha-N1)
interferon (alpha)
interferon (alpha2)
interferon (alpha2a)
interferon (alpha2b)
interferon (alpha2c)
interferon (gamma)
interferon alpha-2b
interleukin-12
interleukin-2
intetumumab
IPH-1101
ipilimumab
ispinesib mesylate
JX-594
kahalalide F
L19-IL2
Lambrolizumab
LEE-011
lenvatinib
lestaurtinib
leukemia vaccine
LGX818
LipoVIL12
litronesib
lonaprisan
lumiliximab
mapatumumab
MDX-1379
MetXia
MGN-1601
midostaurin
mitoxantrone
MKC-1
MKC-1106-MT
mocetinostat
MORAb-004
motexafin gadolinium
navitoclax
nilotinib
noscapine
obinutuzumab
oblimersen sodium
ofatumumab
ON-01910
Oncohist
OncoVAX
P276-00
panobinostat
PAT-SC1
PBI-1402
PCI-24781
peginterferon alfa-2b
pentostatin
perifosine
pimasertib
plitidepsin
poly-ICLC
PX-12
quarfloxacin
quinacrine
R-(-)-gossypol
RAF-265
ramucirumab
razoxane
retaspimycin
rhIFN-alpha
ridaforolimus
rintatolimod
rituximab
sagopilone
sargramostim
SCIB-1
seliciclib
selumetinib
sobuzoxane
SPC-2996
ß-lapachone
SU-6668
sunitinib malate
talminogene laherparepvec
tamibarotene
teniposide
terameprocol
tesetaxel
thalidomide
thymalfasin
tigapotide triflutate
tigatuzumab
tipifarnib
TL-32711
trabedersen
tremelimumab
triciribine phosphate
TRU-016
velimogene aliplasmid
veliparib
vemurafenib
verubulin
vinflunine ditartrate
vitespen
volasertib
volociximab
vosaroxin
XL-147
XL-647
YM-155
zanolimumab
zorubicin

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Triple Analysis: Leukemia, Melanoma and Apoptosis.
    To find out more about Triple Analysis: Leukemia, Melanoma and Apoptosis, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Triple Analysis: Leukemia, Melanoma and Apoptosis is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

Other selected research from the 'Triple Analysis' category:


Triple Analysis: Breast Cancer, Colorectal Cancer and Prostate Cancer
This triple analysis focuses on cancer drug development strategies in Breast Cancer, Colorectal Cancer and Prostate Cancer. Learn More


Triple Analysis: Prostate Cancer, Apoptosis and Antibodies
This triple analysis focuses on cancer drug development strategies in one specific cancer indication (Prostate Cancer), one mechanism/target/effect area (Apoptosis) and one compound specific area (Antibodies). Learn More

Other selected research from the 'Oncology' category:


Protein Kinase Inhibitors Drug Pathway Analyzer
There are today at least 1342 protein kinase inhibitor drugs known to affect more than 251 specific intracellular signaling pathways for the treatment of more than 160 different tumor types. The rational for this plethora of treatment strategies is based on our increasing understanding of the 287 drug targets that are included in this drug-pathway analyzing tool. No less than 280 of these have been recorded with mutations and 57 drug targets have mutations which have been causally implicated in cancer. Learn More


Triple Analysis: Breast Cancer, Lung Cancer and Prostate Cancer
This triple analysis focuses on cancer drug development strategies in Breast Cancer, Lung Cancer and Prostate Cancer. Learn More